2 recruiting, 2 terminated, 1 active not recruiting, 1 completed. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Recruiting 2, Terminated 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Relapsing-Remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-Remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-Remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis BCD-281, Ocrelizumab - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Recruiting | Biocad | 292 | 2025-11-01 | 2026-01-06 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Ocrelizumab (US), Ocrelizumab (EU), ABP 692 - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Active not recruiting | Amgen | 152 | 2025-01-13 | 2026-09-22 |
| Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) treatment withdrawal, Usual DMT continuation, MRI - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Not yet recruiting | University Hospital, Strasbourg, France | 200 | 2025-01-01 | 2025-01-03 |
| Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® Intravenous (IV) infusions - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Completed | Polpharma Biologics S.A. | 265 | 2019-10-01 | 2023-07-03 |
| Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Daclizumab - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Biogen | 41 | 2017-04-18 | 2019-09-27 |
| MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone fingolimod, glatiramer acetate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Novartis Pharmaceuticals | 1064 | 2012-08-09 | 2019-05-28 |
Multiple Sclerosis, Relapsing-Remitting (7) · Multiple Sclerosis (3) · Recurrence (1)
Autoimmune Diseases (7) · Autoimmune Diseases of the Nervous System (7) · Demyelinating Autoimmune Diseases, CNS (7) · Demyelinating Diseases (7) · Immune System Diseases (7) · Nervous System Diseases (7) · Multiple Sclerosis (4) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
ocrelizumab (3) · Glatiramer Acetate (2) · Coat Protein Complex I (1) · Daclizumab (1) · Dimethyl Fumarate (1) · Fingolimod Hydrochloride (1) · Interferon-beta (1) · Rituximab (1) · ofatumumab (1) · teriflunomide (1)
Amgen (1) · Biocad (1) · Biogen (1) · Novartis Pharmaceuticals (1) · Polpharma Biologics S.A. (1) · University Hospital, Montpellier (1) · University Hospital, Strasbourg, France (1)
Canada (3) · France (3) · United States (3) · Croatia (2) · Georgia (2) · Germany (2) · Italy (2) · Poland (2) · Puerto Rico (2) · Serbia (2) · Ukraine (2) · Argentina (1) · Belarus (1) · Belgium (1) · Brazil (1)
PMID 32852530, PMID 36689214, PMID 39749348
2016 (1)